News

The phase III trial has demonstrated that Xofluza was a well-tolerated and efficient potential treatment for flu in otherwise healthy children aged one to less than 12 years

The late-stage trials – ASCLEPIOS I and II probed the efficacy and safety of ofatumumab 20mg given as a once-monthly subcutaneous injection, in comparison to daily once oral

Anifrolumab has demonstrated a statistically-significant and clinically-meaningful reduction in disease activity compared to placebo in the trial.  Both arms received standard of care in the study. Anifrolumab is

VNRX-5133 is an injectable beta-lactamase inhibitor (BLI) that features selective and potent in vitro activity against both serine- and metallo-beta-lactamases (MBLs), including ESBL, OXA, KPC, NDM, and VIM

The Breakthrough Therapy Designation was based on Phase 1 and Phase 2 data evaluating nirogacestat as a monotherapy in patients with desmoid tumors. Desmoid tumors are rare and

The approval has been granted for Tecentriq plus chemotherapy (Abraxane [paclitaxel protein-bound particles for injectable suspension (albumin-bound); nab-paclitaxel]) to treat adult patients with unresectable locally advanced or metastatic

The funding was led by new investor IDG Capital. The existing shareholders Sequoia Capital China, VI Ventures, Legend Star Capital, and LYFE Capital continued to invest. New investors

Fast Track designation is received when a potential new therapy is intended to treat a serious condition and data demonstrate the potential to address an unmet medical need.

Based in Germany, Immatics is a clinical-stage biopharma company engaged in the discovery and development of T-cell redirecting cancer immunotherapies. The German firm is expected to develop T-Cell